In Vivo Molecular Imaging Predicts Therapeutic Response in Ulcerative Colitis

NCT02852850 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2016-10-17

No results posted yet for this study

Summary

Molecular imaging with infliximab antibody with FITC has the potential to predict therapeutic responses to infliximab antibody and can be used for personalized medicine in ulcerative colitis.

Conditions

Sponsors & Collaborators

  • Shandong University

    lead OTHER

Principal Investigators

  • Yanqing Li, MD,PHD · Qilu Hospital of Shandong University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2018-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02852850 on ClinicalTrials.gov